Valerie K. Israel - Concepedia

Concepedia

Author

Valerie K. Israel

University of Southern California

Also Known As

V Israel, Valerie Israel, Valerie K. Israel

18

Publications

1.5K

Citations

11

H-Index

11

Concepts

All Affiliations

University of Southern California USC Norris Comprehensive Cancer Center University of California, Davis University of Maryland, Baltimore Cedars-Sinai Medical Center

VK

About

Valerie K. Israel is an author at University of Southern California specializing in medicine, cancer therapeutics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	92
2	Pharmacology	3	3	80
3	Cancer Therapeutics	3	3	65
4	Pathology	1	1	12
5	Clinical Trials	1	1	31

Valerie K. Israel

×

11

Publications

1.5K

Citations

11

H-Index

	Year	Citations
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Karen Kelly, John Crowley, Paul A. Bunn, Journal of Clinical Oncology	2001	1.1K
Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial Derick Lau, Bryan R. Leigh, David R. Gandara, Journal of Clinical Oncology	2001	97
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V leiden Ilene C. Weitz, Valerie K. Israel, Howard A. Liebman Cancer	1997	58
Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation Ilene C. Weitz, Valerie K. Israel, James Waisman, Thrombosis and Haemostasis	2002	51
MDR1 gene expression in primary and advanced breast cancer. X. Yang, B Uziely, Susan Groshen, PubMed	1999	49
Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials Franco M. Muggia, Davood Vafai, Ronald B. Natale, Lung Cancer OncologyMedicineCancer ManagementClinical TrialsPreliminary Results	1996	31
Intraperitoneal 5-fluoro-2?-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study Valerie K. Israel, Chun Jiang, Franco M. Muggia, Cancer Chemotherapy and Pharmacology Peritoneal CavityPharmacologyToxicologyPharmacotherapyToxicity Study	1995	27
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial Primo Lara, David R. Gandara, Jeff Longmate, Cancer Chemotherapy and Pharmacology OncologyHigh-dose ToremifenePharmacologyPharmacotherapyAnti-cancer Agent	2001	22
Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer Mark A. Socinski, Alan B. Sandler, Langdon L. Miller, Journal of Clinical Oncology	2001	20
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma Mark A. Socinski, Alan B. Sandler, Valerie K. Israel, Cancer	2002	20

Page 1